Monday, 28 May 2018

You are here

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

These rare, severe disorders are often life-threatening and may be associated with high levels of CTL-associated cytokines, chemokines, or cytotoxic proteins, including TNF-α and granulysin.

They studied 96 patients with SJS or TEN in a randomized trial of etanercept versus traditional corticosteroids.

Etanercept was shown to improved clinical outcomes and decrease the SCORTEN-based predicted mortality rate (predicted and observed rates, 17.7% and 8.3%, respectively).

Compared with corticosteroids, etanercept treated patients had a shorter median time to skin healing (14 vs 19 days, respectively; P = 0.010) and lower rates of GI hemorrhage in all SJS-TEN patients (2.6% vs. 18.2%; P = 0.03).

Etanercept was found to decrease TNF-α and granulysin levels in blister fluids and plasma (45.7%–62.5%) and increase the circulating Treg population (2-fold increase; P = 0.002).

Anti–TNF-α therapy may be and effective alternative treatment for CTL-mediated severe skin reactions.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.